Las Vegas, NV -- (SBWIRE) -- 09/21/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.EquityObserver.com issues a special report on the following stocks: CIGNA Corporation(NYSE:CI), NPS Pharmaceuticals, Inc.(NASDAQ: NPSP ) , Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN), BioCryst Pharmaceuticals, Inc.(NASDAQ:BCRX)
CIGNA Corporation(NYSE:CI) managed to keep its gain at 1.12% on above-normal volume of 1.38 million shares. The stock settled at $78.59 after floating in a range of $77.73 to $79.49. Its latest price was $78.59, reaching market capitalization of $22.23 billion. Its 52-week range has been $46.50 to $84.68. Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. The company's Commercial segment offers insured and self-insured medical.
What was the Moving Force behind CI On Bullish Run? Read This Research Report on CI
NPS Pharmaceuticals, Inc.(NASDAQ: NPSP ) traded up on a volume of 3.68 million, higher than its standard daily volume. Shares have gained 4.67% to $30.36. Over the last twelve months, the stock has added 236.47% and faced a best price of $31.72. NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States. Its lead product is Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support.
For How Long NPSP will Fight for Profitability? Read This Trend Analysis report
Achillion Pharmaceuticals, Inc.(NASDAQ:ACHN) traded at $7.29 on above-normal volume of1.05 million shares during the last trading day. The stock has its 12-month high at $6.12 and 52-week low price was $11.36. It traded in a range of $7.19 to $7.43during the last trading day. Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally.
Is ACHN a Solid Investment at These Levels? Read This Report For Details
BioCryst Pharmaceuticals, Inc.(NASDAQ:BCRX) saw its price gain on above-normal volume, as 3.09 million shares changed hands when compared with its average daily volume of 1.56million shares. The stock was up 3.24% to $7.01. It has gained over the last 12 months, increasing 64.17% and marked new low $1.08. BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases.
Why Should Investors Buy BCRX After The Recent Gain? Just Go Here and Find Out
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)